BioCentury
ARTICLE | Distillery Therapeutics

Cancer

June 20, 2017 4:32 PM UTC

Patient sample and cell culture studies suggest α-synuclein inhibitors could help treat melanoma. In patients, tumor levels of α-synuclein were higher in cases of more advanced disease, including metastatic growth phase and vertical growth phase melanoma, than in cases of less advanced disease. In two human melanoma cell lines, an α-synuclein inhibitor tool compound decreased proliferation compared with vehicle and in one of the cell lines, the inhibitor increased cell death. Next steps could include testing other α-synuclein inhibitors in melanoma models.

Prothena Corp. plc and Roche have PRX002 (RG7935), a mAb targeting α-synuclein, in Phase I testing to treat Parkinson's disease...

BCIQ Target Profiles

Alpha synuclein (SNCA)